Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19